K. Gary Barnette Ph.D.
Net Worth
Last updated:
What is K. Gary Barnette Ph.D. net worth?
The estimated net worth of Dr. K. Gary Barnette Ph.D. is at least $4,948,570 as of 16 Dec 2020. He owns shares worth $335,000 as insider, has earned $1,064,500 from insider trading and has received compensation worth at least $3,549,070 in Veru Inc..
What is the salary of K. Gary Barnette Ph.D.?
Dr. K. Gary Barnette Ph.D. salary is $507,010 per year as Chief Scientific Officer in Veru Inc..
How old is K. Gary Barnette Ph.D.?
Dr. K. Gary Barnette Ph.D. is 57 years old, born in 1968.
What stocks does K. Gary Barnette Ph.D. currently own?
As insider, Dr. K. Gary Barnette Ph.D. owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| Veru Inc. (VERU) | Chief Scientific Officer | 100,000 | $3.35 | $335,000 |
What does Veru Inc. do?
Veru Inc., an oncology biopharmaceutical company, focuses on developing medicines for the management of cancers. Its commercial products comprise FC2 female condom/internal condom for the dual protection against unintended pregnancy and the transmission of sexually transmitted infections for ministries of health, government health agencies, U.N. agencies, nonprofit organizations, and commercial partners. The company's development drug candidates include Enobosarm, an oral selective androgen receptor agonist that is in phase III clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; Sabizabulin, which is phase IIb clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; Enobosarm + abemaciclib combination therapy, which is in phase III clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; and Sabizabulin + enobosarm combination therapy, an oral targeted cytoskeleton disruptor plus selective androgen receptor agonist, which is in phase II clinical trial for the treatment of metastatic triple negative breast cancer. Its drug candidates also comprise Sabizabulin, which is in Phase II clinical trial for the treatment of metastatic castration and androgen receptor targeting agent resistant prostate cancer; VERU-100, a GnRH antagonist peptide injection, which is in Phase II clinical trial for the treatment of advanced hormone sensitive prostate cancer; Zuclomiphene Citrate, which is in Phase II clinical trial for treating hot flashes; and Sabizabulin, which is in phase III clinical trial for the treatment of SARS-CoV-2 in subjects at high risk for acute respiratory distress syndrome. In addition, the company is advancing a new drug formulation for the treatment of men with lower urinary tract symptoms from an enlarged prostate. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida.
K. Gary Barnette Ph.D. insider trading
Veru Inc.
Dr. K. Gary Barnette Ph.D. has made only one insider trade between 2018-2020, according to the Form 4 filled with the SEC. He sold 100,000 units of VERU stock worth $1,064,500 on 16 Dec 2020.
As of 16 Dec 2020 he still owns at least 100,000 units of VERU stock.
Veru key executives
Veru Inc. executives and other stock owners filed with the SEC:
- Dr. Harry Fisch (66) Vice Chairman & Chief Corporation Officer
- Dr. K. Gary Barnette Ph.D. (57) Chief Scientific Officer
- Dr. Mitchell S. Steiner F.A.C.S., M.D., F.A.C.S (64) Chairman, Pres & Chief Executive Officer
- Ms. Michele Greco (66) Chief Financial Officer & Chief Admin. Officer